In two Phase 1a studies, AVL-292 demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy volunteers.
The trial is investigating the pharmacokinetics, safety and tolerability profile of VL-292 as monotherapy in 28-day cycles in subjects with relapsed and/or refractory B-NHL, CLL and Waldenstrom’s Macroglobulinemia.